�Intervention Triage strategY study, published in the September 2, 2008 issue of the Journal of American College of Cardiology, shows that Angiomax� (bivalirudin) monotherapy provides hold in and high-risk (unstable angina (UA)/non - ST elevation myocardial infarct) acute coronary thrombosis syndrome (ACS) patients , world Health Organization are undergoing percutaneous coronary intervention (PCI), with similar results from ischemic events and death versus standard therapy (unfractionated heparin [UFH] or enoxaparin plus a glycoprotein [GP] IIb/IIIa inhibitor) as metric at one-year post-PCI.
Additionally, as antecedently reported in The Lancet1 patients in the PCI subset of ACUITY wHO were toughened with Angiomax experienced a 41% simplification in hemorrhage at 30 days compared to criterion treatment.
"These findings ar important as the information suggest treatment with Angiomax provides similar protection against ischemia and death over standard therapy at 1-year. Furthermore, at 30 days we saw Angiomax decreased major bleeding. Multiple studies have shown a significant association between bleeding complications in ACS and PCI with mortality rate," said Harvey White, MD, Green Lane Hospital, Auckland, New Zealand, Department of Cardiology, one of master investigators and author of the study. "The data from the ACUITY sub-analysis suggest treatment with Angiomax is an attractive antithrombotic therapeutic option for patients undergoing PCI."
The analysis of the ACUITY-PCI subset assessed the impact of treatment with Angiomax inside 30 years and on 1-year outcomes in 7,789 tone down and speculative ACS patients undergoing PCI compared to standard therapy. In the study, patients were randomized to UFH or enoxaparin plus a GP IIb/IIIa inhibitor, Angiomax plus a GP IIb/IIIa inhibitor, or Angiomax alone. Endpoints included assessment of composite ischemia, defined as death, myocardial infarction, or unplanned revascularization, mortality at 1-year and highlighted the impact of bleeding.
Specifically, the results of the ACUITY trial in patients undergoing PCI showed that:
- Patients treated with Angiomax experienced comparable composite ischemia (death, myocardial infarct or unwitting revascularization) and mortality at 1-year compared to patients treated with standard therapy.
-- Composite ischemia results were 19.2% bivalirudin alone,
19.4% bivalirudin plus a GP llb/llla inhibitor vs. 17.8%
UFH/ enoxaparin plus a GP llb/llla inhibitor
-- Mortality results were 3.1% bivalirudin alone, 3.3%
bivalirudin plus a GP llb/llla inhibitor vs. 3.2%
UFH/enoxaparin asset a GP llb/llla inhibitor
- A 30-day analysis showed major bleeding occurred in 7% of the UFH/enoxaparin addition GP IIb/IIIa inhibitor grouping compared to 4% in the Angiomax alone group (p
- Patients who experient major bleeding significantly yearner hospital stays than those who did not experience a major bleed (5.0 days vs. 3.0 years, respectively (p
"These information at 1-year show that Angiomax continues to certify safety and efficacy for a full year following a patient's angioplasty. This is simply the latest analysis from seven major randomized trials in intimately 25,000 patients systematically demonstrating Angiomax offers improved outcomes for angioplasty patients compared to standard therapy," said John Kelley, President, Chief Operating Officer, The Medicines Company. "Additionally, Angiomax may assist reduce hospital costs, in particular because of the reductions we bear observed in major haemorrhage complications. With approximately i million PCI procedures performed in the U.S. per year, incremental cost nest egg may outcome in significant overall nest egg to the health care system."
About Angiomax
Angiomax is a direct thrombin inhibitor with a by nature reversible mechanism of action and 25 minute half life. In clinical trials, treatment with Angiomax resulted in improved clinical outcomes with significantly rock-bottom rates of major bleeding compared to heparin addition GPI across the total spectrum of risk in patients undergoing PCI and numerically turn down rates of 1-year mortality in patients undergoing PCI.
In the United States, Angiomax with provisional GPI is indicated in patients undergoing angioplasty, also called PCI, and in patients with, or at danger of, heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. In addition, Angiomax is indicated for purpose as an anticoagulant in patients with UA undergoing percutaneous transluminal coronary angioplasty (PTCA). Angiomax is intended for utilization with st. Joseph. The most common adverse events for Angiomax in clinical trials comparing Angiomax and liquaemin were indorse pain, pain, nausea, cephalalgia, and hypotension. The incidence of these adverse events was comparable in both the Angiomax and lipo-Hepin groups in these trials. An unexplained fall in blood pressure or hematocrit, or whatever unexplained symptom, should lead to grave consideration of a haemorrhagic event and cessation of Angiomax giving medication. Angiomax is contraindicated in patients with active major bleeding or hypersensitivity to Angiomax or its components. Please see full prescribing information available at hypertext transfer protocol://www.angiomax.com.
About The Medicines Company
The Medicines Company (NASDAQ: MDCO) is focused on advancing the handling of critical care patients through the delivery of innovative, cost-efficient medicines to the worldwide hospital market. The Company markets Angiomax� (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty and Cleviprex� (clevidipine butyrate) injectable emulsion in the United States for the diminution of rip pressure when oral therapy is non feasible or not desirable. The Company also has an investigational antiplatelet agent, cangrelor, in late-stage evolution and a serine peptidase inhibitor, CU-2010, in early-stage development. The Company's internet site is hTTP://www.themedicinescompany.com.
Statements contained in this weigh release most The Medicines Company that are not purely diachronic, and all other statements that are not purely historical, whitethorn be deemed to be forward-looking statements for purposes of the safe harbour provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and alike expressions ar intended to identify advanced statements. These forward-looking statements involve known and unknown risks and uncertainties that may grounds the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may grounds or put up to such differences include whether whether physicians, patients and other key decision-makers will accept clinical visitation results,, whether the Company will be able to obtain regulative approvals and such other factors as are fructify forth in the risk factors elaborated from time to time in the Company's occasional reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the danger factors detailed in the Company's Quarterly Report on Form 10-Q filed on August 11, 2008, which are incorporated herein by reference. The Company specifically disclaims whatsoever obligation to update these forward-looking statements.
1 G . Stone , H . White , E . Ohman , et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization nd Urgent Intervention Triage strategy (ACUITY) trial. The Lancet. 2007;369:907 - 919.
Angiomax
View do drugs information on Angiomax.
More information
Saturday 6 September 2008
Sunday 17 August 2008
Justice Struggle to Find New Ways to Ask You to Shake Your Booty
Photo: Marco Dos Santos
"To have so many difficulties to write the lyrics for 'D.A.N.C.E.' � we were just trying to find something not too serious and not too narrative, because it's boring or cheesy. Something a bit more than 'Shake your body to the ground' or 'Can you feel the vibe?' or 'Do you feel the funk?'" �Justice's Xavier de Rosnay finally explains the origins of "Do the D.A.N.C.E. / Stick to the B.E.A.T." [Pitchfork]
"I remember going, 'Wait a minute, I don't know how to play this scene � Joan is being really nice.'" �Christina Hendricks of Mad Men [Watcher/Chicago Tribune]
"My mother still thinks that being a paralegal is the greatest job possible. Even when I told my mother they're going to greenlight the movie, that they're going to start shooting it, she was like: 'You know what? I got these brochures about being a paralegal. You should check it out.'" �Michael C. Martin, former MTA employee and writer of the currently shooting movie Brooklyn's Finest [NYT]
"There are two kinds of men on Earth. The ones who wouldn't want to date Nellie Oleson on a dare, and those who want to date Nellie Oleson a little too much � and wanted me to wear the wig. So I could only have sex with people who had never seen the show.'" �Alison Arngrim on Little House on the Prairie [NYDN]
"I've been pitying fools for 28 years, Bill, and it's never personal." �Mr. T [Fox]
More info
Thursday 7 August 2008
Kratornas
Artist: Kratornas
Genre(s):
Metal: Death,Black
Discography:
The Onlsaught Of Battledemons
Year: 1999
Tracks: 6
Monday 30 June 2008
L.S.G.
Artist: L.S.G.
Genre(s):
R&B: Soul
Discography:
The Best Of L.S.G. CD2
Year: 2004
Tracks: 10
The Best Of L.S.G. CD1
Year: 2004
Tracks: 9
Wednesday 25 June 2008
Alberta Idol hopefuls
Being from a small city or town may not shape a star in the same way as being from a big city would, but it definitely has its own advantages.
Canadian Idol�s Top 24 competitor Theo Tams, a 22-year-old student from Lethbridge Alta., says that in its own unique way, being from a small town has prepared him for what to expect if he makes it big.
�I grew up in a small town of just over 6,000 people where everybody knew everybody, anonymity was pretty much non-existent,� Tams tells Metro.
�Now that I am in Canadian Idol and starting to be recognized, it�s almost easier to deal with because I�m kind of used to everyone knowing who I am,� he says. �The whole �small town big dreams� clich� exists for a reason.�
Tams says when you grow up in a small town, you learn to appreciate things a little more than people from a bigger city who probably would like getting even the smallest amount of exposure.
For people like Tams and fellow Top 24 member Amberly Thiessen, it�s a blessing you don�t take lightly.
�I think that being from a small town and then moving to a big city really opens the mind and well rounds an individual,� says Thiessen, 19, from Seven Persons, Alta. �Not only does that person know the excitement of a big city, they also know the feeling of a small town. They have experienced both ends of the spectrum and can relate to a larger amount of people.�
When you�re from a small town like Lethbridge or Seven Persons, past seasons of Canadian Idol has demonstrated that the support these hopefuls get tend to be stronger than someone from a bigger city.
�In a small town everyone knows everyone and your fan base is tighter,� says Thiessen. �In a large city you don�t run into everyone more often like you would in a small community. Your face is more familiar.�
>> For more on Canadian Idol, go to www.metronews.ca/idol.
See Also
Tuesday 24 June 2008
Gyuto Monks
Artist: Gyuto Monks
Genre(s):
Blues
Other
Discography:
World Sounds
Year:
Tracks: 1
Freedom Chants from the Roof of the World
Year:
Tracks: 3
Robert De Niro - De Niro Denies Being Difficult
Movie star ROBERT DE NIRO has blasted rumours he is difficult to work with on movie sets - insisting he would never make the filming process more difficult than it already is.
The veteran star refutes he has trouble working in harmony with fellow actors and directors - and claims he is nowhere near as hard to work with compared to other industry insiders.
He says, "Difficult? Me? I don't think I am difficult compared to other people. It is hard to make movies at the best of times, so you don't want to give people a hard time. People have their own agendas.
"You can look into my background all you like, but I have never had problems with authority on film sets. Even if I disagree with a film director, I work through it."
See Also
Subscribe to:
Posts (Atom)